Inventiva S.A. (IVA) Bundle
An Overview of Inventiva S.A. (IVA)
General Summary of Inventiva S.A. (IVA)
Inventiva S.A. is a biotechnology company founded in 2011 and headquartered in Daix, France. The company specializes in developing innovative therapies for treating serious diseases with significant unmet medical needs.
Company Products and Services
Key product portfolio includes:
- Lanifibranor - treatment for non-alcoholic steatohepatitis (NASH)
- Odiparcil - potential treatment for mucopolysaccharidosis (MPS)
- Mavacamten - cardiovascular therapeutic development
Financial Performance 2023
| Financial Metric | Amount (€) |
|---|---|
| Total Revenue | 14.8 million |
| Research & Development Expenses | 22.1 million |
| Cash Position | 63.4 million |
Market Position
Inventiva S.A. is recognized as a pioneering biotechnology company in rare disease therapeutics, with a strong focus on innovative drug development.
Clinical Development Highlights
- Lanifibranor Phase 3 NATIVE clinical trial for NASH ongoing
- Confirmed FDA Fast Track Designation for lead therapeutic program
- Active partnerships with global pharmaceutical research organizations
Market Capitalization
| Stock Exchange | Symbol | Market Cap |
|---|---|---|
| Euronext Paris | IVA | €184.2 million |
Mission Statement of Inventiva S.A. (IVA)
Mission Statement of Inventiva S.A. (IVA)
Inventiva S.A. (IVA) 2024 mission statement focuses on advancing therapeutic solutions in specific medical domains.
Core Mission Components
| Component | Specific Details |
|---|---|
| Research Focus | Rare fibrotic diseases and metabolic disorders |
| Therapeutic Areas | Systemic sclerosis, non-alcoholic steatohepatitis (NASH), and mucopolysaccharidosis |
| Development Stage | Clinical-stage biopharmaceutical company |
Key Research Priorities
- Lanifibranor for systemic sclerosis
- Odiparcil for mucopolysaccharidosis
- IVA336 for metabolic disorders
Research Investment
Research and development expenditure in 2023: €16.9 million
Clinical Pipeline Metrics
| Program | Current Phase | Patient Enrollment |
|---|---|---|
| Lanifibranor | Phase III | 475 patients |
| Odiparcil | Phase II | 62 patients |
Strategic Objectives
- Develop innovative therapeutic solutions
- Address unmet medical needs
- Advance precision medicine approaches
Cash and cash equivalents as of December 31, 2023: €57.1 million
Vision Statement of Inventiva S.A. (IVA)
Vision Statement Analysis of Inventiva S.A. (IVA) in 2024
Strategic Vision ComponentsInventiva S.A.'s vision statement for 2024 focuses on advancing therapeutic innovations in specific medical domains.
Pharmaceutical Research Focus
Key Research Domains| Research Area | Primary Target | Current Development Stage |
|---|---|---|
| Lanifra (NASH Treatment) | Liver Fibrosis | Phase 2b Clinical Trials |
| Mavacamten (Cardiac Condition) | Hypertrophic Cardiomyopathy | Advanced Clinical Research |
Therapeutic Innovation Strategy
Research Investment Metrics- R&D Expenditure in 2023: €14.3 million
- Research Personnel: 72 specialized scientists
- Patent Portfolio: 18 active pharmaceutical patents
Global Market Positioning
International Development TargetsInventiva targets expansion in European and North American pharmaceutical markets with specialized therapeutic solutions.
| Geographic Market | Market Entry Strategy | Projected Investment |
|---|---|---|
| European Union | Direct Clinical Collaboration | €6.7 million |
| United States | Partnership Development | €5.2 million |
Core Values of Inventiva S.A. (IVA)
Inventiva S.A. Core Values Framework 2024
Innovation and Scientific ExcellenceInventiva S.A. demonstrates commitment to innovation through targeted research and development investments.
| R&D Investment 2023 | Research Personnel |
|---|---|
| €8.4 million | 42 dedicated researchers |
- Focus on rare disease therapeutic developments
- Advanced molecular screening technologies
- Proprietary drug discovery platforms
Commitment to transparent and responsible drug development processes.
| Clinical Trial Compliance | Regulatory Approvals 2023 |
|---|---|
| 100% ICH-GCP standards adherence | 3 new regulatory submissions |
Prioritizing patient outcomes and therapeutic effectiveness.
- Rare disease treatment pipeline
- Personalized medicine research
- Patient engagement programs
| Environmental Investment | Carbon Reduction |
|---|---|
| €620,000 green initiatives | 12% carbon footprint reduction |
Inventiva S.A. (IVA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.